NAMS
NAMS clinical trials: NewAmsterdam Pharma Co N.V.
Every trial on ClinicalTrials.gov where NewAmsterdam Pharma Co N.V. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 21
- Trials linked
- 20
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
NAMS on the catalyst calendar · NAMS registry changes
- Primary completion Sep 2028Sponsor estimatePhase 2NCT07794670Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's DiseaseNewAmsterdam Pharma · Preclinical Alzheimer's DiseaseRecruitingNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2028Sponsor estimatePhase 3NCT07219602A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of...NewAmsterdam Pharma · LipidemiaActive, not recruitingNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 2NCT06496243Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) LevelsNewAmsterdam Pharma · DyslipidemiasRecruitingNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2027Sponsor estimatePhase 3NCT06305559A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary PlaqueNewAmsterdam Pharma · LipidemiaActive, not recruitingNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2026Sponsor estimatePhase 2NCT06982508Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy VolunteersNewAmsterdam Pharma · Antioxidant AbsorptionRecruitingNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 25, 2024ActualPhase 3NCT06005597Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying TherapiesNewAmsterdam Pharma · DyslipidemiasCompletedNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 26, 2024ActualPhase 3NCT05142722Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying TherapiesNewAmsterdam Pharma · DyslipidemiasCompletedNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 28, 2024ActualPhase 3NCT05425745Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.NewAmsterdam Pharma · DyslipidemiasCompletedNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2, 2023ActualPhase 1NCT06081166A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and RosuvastatinNewAmsterdam Pharma · Healthy VolunteersCompletedNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 9, 2023ActualPhase 2NCT05161715Proof-of-concept, Open-label Study in Patients With Early Alzheimer's DiseaseNewAmsterdam Pharma · Early Alzheimer's DiseaseCompletedNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 12, 2024ActualPhase 1NCT06547359A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult SubjectsNewAmsterdam Pharma · Healthy VolunteersCompletedNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 24, 2023ActualPhase 2NCT05421078A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.NewAmsterdam Pharma · DyslipidemiaCompletedNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 25, 2024ActualPhase 1NCT06250205Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without ObicetrapibNewAmsterdam Pharma · Healthy VolunteersCompletedNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 12, 2024ActualPhase 1NCT06048302PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic FunctionNewAmsterdam Pharma · Hepatic ImpairmentCompletedNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 26, 2024Sponsor estimatePhase 1NCT05972278Investigating the Effect of Obicetrapib on Lipoprotein MetabolismNewAmsterdam Pharma · Lipid MetabolismUnknown statusNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 24, 2021ActualPhase 2NCT04753606Randomized Study of Obicetrapib as an Adjunct to Statin TherapyNewAmsterdam Pharma · DyslipidemiasCompletedNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 12, 2022ActualPhase 2NCT05266586Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS TherapyNewAmsterdam Pharma · DyslipidemiasCompletedNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 7, 2024ActualPhase 1NCT06050291Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and EzetimibeNewAmsterdam Pharma · Healthy Volunteer StudyCompletedNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 3NCT05202509Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular DiseaseNewAmsterdam Pharma · Atherosclerotic Cardiovascular DiseaseActive, not recruitingNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 7, 2021ActualPhase 2NCT04770389Randomized Study of Obicetrapib in Combination With EzetimibeNewAmsterdam Pharma · DyslipidemiasCompletedNAMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimateNo phase registeredNCT07478887Impact of the Corrie Lipids Digital Health Program on Lipid OptimizationJohns Hopkins University · Cardiovascular RiskRecruitingAMGNCollaboratorNAMSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 21 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner